Evotec (EVO) said early Wednesday it will join the NURTuRE-AKI consortium to establish a patient cohort for acute kidney injury.
The consortium focuses on adult and pediatric cardiac surgery patients who are at high risk of developing acute kidney injury, as well as patients undergoing progression to chronic kidney disease.
Evotec expects the initiative to support the discovery of treatments for acute kidney injury patients based on a molecular level of understanding of the disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.